Biofrontera Inc Net Assets
Biofrontera Inc net assets. Based on the latest financial reports, Biofrontera Inc (BFRI) has net assets worth $5.96 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($24.06 Million) and total liabilities ($18.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Biofrontera Inc growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.96 Million |
| % of Total Assets | 24.75% |
| Annual Growth Rate | N/A |
| 5-Year Change | -7.57% |
| 10-Year Change | N/A |
| Growth Volatility | 81.62 |
Net Assets of Biofrontera Inc (2019–2025)
Net assets of Biofrontera Inc from 2019 to 2025. This chart illustrates how Biofrontera Inc's net assets have evolved over time, based on quarterly financial data. See net asset quality index of Biofrontera Inc to measure how much of total assets are equity-financed.
Annual Net Assets for Biofrontera Inc (2019–2025)
The table below shows the annual net assets of Biofrontera Inc from 2019 to 2025. For live market cap and overall valuation, see BFRI market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $10.48 Million | +136.41% |
| 2024-12-31 | $4.43 Million | -7.51% |
| 2023-12-31 | $4.79 Million | -79.93% |
| 2022-12-31 | $23.88 Million | +110.60% |
| 2021-12-31 | $11.34 Million | +94.54% |
| 2020-12-31 | $5.83 Million | +119.31% |
| 2019-12-31 | $-30.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biofrontera Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9776600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Biofrontera Inc Net Assets Breakdown (December 2025)
Biofrontera Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.00K | 0.11% |
| Other Components | $138.41 Million | 1320.73% |
| Total Equity | $10.48 Million | 100.00% |
Biofrontera Inc Competitors by Market Cap
The table below lists competitors of Biofrontera Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MESB Bhd
KLSE:7234
|
$13.22 Million |
|
Mr. Onion
TWO:2740
|
$13.22 Million |
|
ABERA BIOSCIENCE AB
F:8WK
|
$13.23 Million |
|
Cardiex Ltd
AU:CDX
|
$13.23 Million |
|
Venteny Fortuna International
JK:VTNY
|
$13.22 Million |
|
Arcoma AB
ST:ARCOMA
|
$13.21 Million |
|
Elementis PLC
LSE:ELM
|
$13.21 Million |
|
OXE Marine AB
ST:OXE
|
$13.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biofrontera Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,433,000 to 10,480,000, a change of 6,047,000 (136.4%).
- Net loss of 10,536,000 reduced equity.
- New share issuances of 10,850,000 increased equity.
- Other factors increased equity by 5,733,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.54 Million | -100.53% |
| Share Issuances | $10.85 Million | +103.53% |
| Other Changes | $5.73 Million | +54.7% |
| Total Change | $- | 136.41% |
Book Value vs Market Value Analysis
This analysis compares Biofrontera Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.99x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-49.72 | $0.89 | x |
| 2020-12-31 | $10.05 | $0.89 | x |
| 2021-12-31 | $13.26 | $0.89 | x |
| 2022-12-31 | $22.59 | $0.89 | x |
| 2023-12-31 | $3.10 | $0.89 | x |
| 2024-12-31 | $0.80 | $0.89 | x |
| 2025-12-31 | $0.90 | $0.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biofrontera Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -100.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -25.26%
- • Asset Turnover: 1.46x
- • Equity Multiplier: 2.73x
- Recent ROE (-100.53%) is above the historical average (-206.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -41.95% | 0.91x | 0.00x | $-7.96 Million |
| 2020 | -188.52% | -58.29% | 0.78x | 4.14x | $-11.57 Million |
| 2021 | -332.62% | -156.49% | 0.45x | 4.69x | $-38.85 Million |
| 2022 | -2.68% | -2.23% | 0.56x | 2.13x | $-3.03 Million |
| 2023 | -420.01% | -59.09% | 1.22x | 5.83x | $-20.61 Million |
| 2024 | -400.61% | -47.61% | 1.69x | 4.99x | $-18.20 Million |
| 2025 | -100.53% | -25.26% | 1.46x | 2.73x | $-11.58 Million |
Industry Comparison
This section compares Biofrontera Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $86,713,726
- Average return on equity (ROE) among peers: 26.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biofrontera Inc (BFRI) | $5.96 Million | 0.00% | 3.04x | $13.22 Million |
| Aurora Cannabis Inc (ACB) | $1.71 Million | -2.57% | 0.01x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $335.50 Million | -73.41% | 0.53x | $143.73 Million |
| Akanda Corp (AKAN) | $4.28 Million | -95.78% | 0.85x | $584.11K |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $194.43 Million |
| Alkermes Plc (ALKS) | $18.84 Million | -398.98% | 9.71x | $7.67 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-151.17 Million | 0.00% | 0.00x | $3.25 Billion |
| Amphastar P (AMPH) | $233.44 Million | 7.75% | 0.36x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $5.96 Million | 1208.40% | 615.85x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $208.93 Million | -62.22% | 17.18x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $135.63 Million | 15.17% | 0.15x | $260.30 Million |
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquarte… Read more